TWI749881B - 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 - Google Patents
二氧代哌類衍生物、其製備方法及其在醫藥上的應用 Download PDFInfo
- Publication number
- TWI749881B TWI749881B TW109140529A TW109140529A TWI749881B TW I749881 B TWI749881 B TW I749881B TW 109140529 A TW109140529 A TW 109140529A TW 109140529 A TW109140529 A TW 109140529A TW I749881 B TWI749881 B TW I749881B
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- chloro
- tert
- mmol
- dioxopiper
- Prior art date
Links
- 0 CNC(N(CC1)CCC11OCC(*)C1)=O Chemical compound CNC(N(CC1)CCC11OCC(*)C1)=O 0.000 description 15
- PVQGJWKXCJYOCP-HVNZXBJASA-N CC(C)C[C@@H](CO)NC(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O Chemical compound CC(C)C[C@@H](CO)NC(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O PVQGJWKXCJYOCP-HVNZXBJASA-N 0.000 description 2
- BJROGYBLZHRIGU-FRSAAGAISA-N COC(CC1)CCC1N(CCN1c2ccc(C[C@@H](C(O)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)cc2)CC1=O Chemical compound COC(CC1)CCC1N(CCN1c2ccc(C[C@@H](C(O)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)cc2)CC1=O BJROGYBLZHRIGU-FRSAAGAISA-N 0.000 description 2
- FYIIXSFUZPOLMV-UHFFFAOYSA-N OC(CC1)CCC1N(CCN1)CC1=O Chemical compound OC(CC1)CCC1N(CCN1)CC1=O FYIIXSFUZPOLMV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N C1NCCOC1 Chemical compound C1NCCOC1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- NYQBECRYPIWLOX-PLAQUJHSSA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(C1)C(CC2)CCC2OC)C1=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(C1)C(CC2)CCC2OC)C1=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O NYQBECRYPIWLOX-PLAQUJHSSA-N 0.000 description 1
- NCPPVBTZUUJEDI-XUYPSIEWSA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(C1)C2CC(CO)C2)C1=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(C1)C2CC(CO)C2)C1=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O NCPPVBTZUUJEDI-XUYPSIEWSA-N 0.000 description 1
- MGWCZLZCVCYFEK-OVUYURIWSA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CC1COCC1)C1)C1=O)N(CCN(c1cc(Cl)ccc1N(CC=C)CC=C)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CC1COCC1)C1)C1=O)N(CCN(c1cc(Cl)ccc1N(CC=C)CC=C)C1=O)C1=O)=O MGWCZLZCVCYFEK-OVUYURIWSA-N 0.000 description 1
- KKBHWPFLBNDFND-ZUILJJEPSA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CC1COCC1)C1)C1=O)N(CCN(c1cc(Cl)ccc1N)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CC1COCC1)C1)C1=O)N(CCN(c1cc(Cl)ccc1N)C1=O)C1=O)=O KKBHWPFLBNDFND-ZUILJJEPSA-N 0.000 description 1
- KWHZHJPWXDCENS-VWLOTQADSA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CCOC)C1)C1=O)N(CCN(c(cc(cc1)Cl)c1N)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CCOC)C1)C1=O)N(CCN(c(cc(cc1)Cl)c1N)C1=O)C1=O)=O KWHZHJPWXDCENS-VWLOTQADSA-N 0.000 description 1
- DJLAXPYZIXCTTE-SANMLTNESA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CCOC)C1)C1=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1N(CCN(CCOC)C1)C1=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O DJLAXPYZIXCTTE-SANMLTNESA-N 0.000 description 1
- VNVFELILPBFMIB-FQEVSTJZSA-N CC(C)(C)OC([C@H](Cc(cc1)ccc1[N+]([O-])=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc(cc1)ccc1[N+]([O-])=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O VNVFELILPBFMIB-FQEVSTJZSA-N 0.000 description 1
- XENJOJUXBWRBCA-FQEVSTJZSA-N CC(C)(C)OC([C@H](Cc1ccccc1)N(CCN(c1cc(C)ccc1[N+]([O-])=O)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc1ccccc1)N(CCN(c1cc(C)ccc1[N+]([O-])=O)C1=O)C1=O)=O XENJOJUXBWRBCA-FQEVSTJZSA-N 0.000 description 1
- BAXIMXOYXFZZEO-IBGZPJMESA-N CC(C)(C)OC([C@H](Cc1ccccc1)N(CCN(c1cc(Cl)ccc1N)C1=O)C1=O)=O Chemical compound CC(C)(C)OC([C@H](Cc1ccccc1)N(CCN(c1cc(Cl)ccc1N)C1=O)C1=O)=O BAXIMXOYXFZZEO-IBGZPJMESA-N 0.000 description 1
- WSFFATKRCOYBOF-WBNZYJNCSA-N CC(C)(C)OC(c1cc(cc(cc2)NC([C@H](Cc(cc3)ccc3N(CCN(C3)C(CC4)CCC4O)C3=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)=O)c2[nH]1)=O Chemical compound CC(C)(C)OC(c1cc(cc(cc2)NC([C@H](Cc(cc3)ccc3N(CCN(C3)C(CC4)CCC4O)C3=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)=O)c2[nH]1)=O WSFFATKRCOYBOF-WBNZYJNCSA-N 0.000 description 1
- YZWDEGMXFZIHIT-UHFFFAOYSA-N CC(C)(C)OC(c1cc2cc(N)ccc2[o]1)=O Chemical compound CC(C)(C)OC(c1cc2cc(N)ccc2[o]1)=O YZWDEGMXFZIHIT-UHFFFAOYSA-N 0.000 description 1
- AVQWNZMVGKBRJV-VQQBPFSGSA-N CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C(CC4)CCC4OC)C3=O)N(CCN(c3cc(C)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C(CC4)CCC4OC)C3=O)N(CCN(c3cc(C)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O AVQWNZMVGKBRJV-VQQBPFSGSA-N 0.000 description 1
- GUPHCBVZHBLPDT-QBCXNKOLSA-N CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C(CC4)CCC4OC)C3=O)N(CCN(c3cc(Cl)ccc3N3[NH+](CC(C)(C)OC(c4cc5cc(N)ccc5[n]4C(OC(C)(C)C)=O)=O)[N-]N=C3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C(CC4)CCC4OC)C3=O)N(CCN(c3cc(Cl)ccc3N3[NH+](CC(C)(C)OC(c4cc5cc(N)ccc5[n]4C(OC(C)(C)C)=O)=O)[N-]N=C3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O GUPHCBVZHBLPDT-QBCXNKOLSA-N 0.000 description 1
- YXRQNTVLFKWEIZ-KDXMTYKHSA-N CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C4CCOCC4)C3=O)N(CCN(c3cc(C)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C4CCOCC4)C3=O)N(CCN(c3cc(C)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O YXRQNTVLFKWEIZ-KDXMTYKHSA-N 0.000 description 1
- SKFJVANBMQDUNN-QNGWXLTQSA-N CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(CCOC)C3)C3=O)N(CCN(c3cc(C)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(CCOC)C3)C3=O)N(CCN(c3cc(C)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[n]1C(OC(C)(C)C)=O)=O SKFJVANBMQDUNN-QNGWXLTQSA-N 0.000 description 1
- KYRABFQQIUUZTH-YDYNHKSESA-N CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3NC(N3[C@@H](CO)CCC3)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O Chemical compound CC(C)(C)OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3NC(N3[C@@H](CO)CCC3)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O KYRABFQQIUUZTH-YDYNHKSESA-N 0.000 description 1
- JOAPRIPBRKUTHQ-UHFFFAOYSA-N CC(C)(C)OC(c1cc2cc([N+]([O-])=O)ccc2[o]1)=O Chemical compound CC(C)(C)OC(c1cc2cc([N+]([O-])=O)ccc2[o]1)=O JOAPRIPBRKUTHQ-UHFFFAOYSA-N 0.000 description 1
- OPQJUUKVOZXGMD-SANMLTNESA-N CC(C)(C)ONC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CC(C)(C)ONC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O OPQJUUKVOZXGMD-SANMLTNESA-N 0.000 description 1
- ORJFFKQTSKDGFE-KNQAVFIVSA-N CC(C)[C@@H](CO)NC(Nc1ccc(C[C@@H](C(N)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O Chemical compound CC(C)[C@@H](CO)NC(Nc1ccc(C[C@@H](C(N)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O ORJFFKQTSKDGFE-KNQAVFIVSA-N 0.000 description 1
- NWYYWIJOWOLJNR-YFKPBYRVSA-N CC(C)[C@H](CO)N Chemical compound CC(C)[C@H](CO)N NWYYWIJOWOLJNR-YFKPBYRVSA-N 0.000 description 1
- MJSFVEKMLJYCOU-DEOSSOPVSA-N CCN(CC=C)c(c(N(CCN([C@@H](Cc(cc1)ccc1Br)C(OC(C)(C)C)=O)C1=O)C1=O)c1)ccc1Cl Chemical compound CCN(CC=C)c(c(N(CCN([C@@H](Cc(cc1)ccc1Br)C(OC(C)(C)C)=O)C1=O)C1=O)c1)ccc1Cl MJSFVEKMLJYCOU-DEOSSOPVSA-N 0.000 description 1
- UZVKEIDHDCJKMP-DPENGREQSA-N CCN(CC=C)c(c(N(CCN([C@@H](Cc(cc1)ccc1N(CCN(C1)C(CC2)CCC2O)C1=O)C(OC(C)(C)C)=O)C1=O)C1=O)c1)ccc1Cl Chemical compound CCN(CC=C)c(c(N(CCN([C@@H](Cc(cc1)ccc1N(CCN(C1)C(CC2)CCC2O)C1=O)C(OC(C)(C)C)=O)C1=O)C1=O)c1)ccc1Cl UZVKEIDHDCJKMP-DPENGREQSA-N 0.000 description 1
- FCRBFUXFNUWNLP-URXFXBBRSA-N CCNC([C@H](Cc(cc1)ccc1NC(N1C[C@@H](CO)OCC1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CCNC([C@H](Cc(cc1)ccc1NC(N1C[C@@H](CO)OCC1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O FCRBFUXFNUWNLP-URXFXBBRSA-N 0.000 description 1
- MBAIPQWIIKZXMP-VWLOTQADSA-N CCNC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CCNC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O MBAIPQWIIKZXMP-VWLOTQADSA-N 0.000 description 1
- VVSASNKOFCZVES-UHFFFAOYSA-N CN(C(CC(N1C)=O)=O)C1=O Chemical compound CN(C(CC(N1C)=O)=O)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 1
- YHXLHDXGHRLVOG-DEOSSOPVSA-N CNC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound CNC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O YHXLHDXGHRLVOG-DEOSSOPVSA-N 0.000 description 1
- MUVQIIBPDFTEKM-IUYQGCFVSA-N C[C@@H]([C@@H](CO)N)O Chemical compound C[C@@H]([C@@H](CO)N)O MUVQIIBPDFTEKM-IUYQGCFVSA-N 0.000 description 1
- MLGRXXUVWDQCGB-IQVOZAENSA-N C[C@H]([C@@H](CO)NC(Nc1ccc(C[C@@H](C(N)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O)O Chemical compound C[C@H]([C@@H](CO)NC(Nc1ccc(C[C@@H](C(N)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O)O MLGRXXUVWDQCGB-IQVOZAENSA-N 0.000 description 1
- FMMLUURMUJLKDK-AAFRUZDHSA-N C[C@H]([C@@H](CO)NC(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O)O Chemical compound C[C@H]([C@@H](CO)NC(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O)O FMMLUURMUJLKDK-AAFRUZDHSA-N 0.000 description 1
- KKTOCZWHPXPRCV-MDCBZVBUSA-N C[C@H]([C@@H](CO)NC(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(OC(C)(C)C)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O)O Chemical compound C[C@H]([C@@H](CO)NC(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(OC(C)(C)C)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O)O KKTOCZWHPXPRCV-MDCBZVBUSA-N 0.000 description 1
- ABBSHXCCBYBHRW-UUVTXVRHSA-N Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2N(CCN(C2)C(CC3)CCC3OC)C2=O)C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)C2=O)C2=O)ccc1-[n]1nnnc1 Chemical compound Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2N(CCN(C2)C(CC3)CCC3OC)C2=O)C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)C2=O)C2=O)ccc1-[n]1nnnc1 ABBSHXCCBYBHRW-UUVTXVRHSA-N 0.000 description 1
- OZAVUGADTXNPNM-UMSFTDKQSA-N Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2N(CCN(C2)C3CCOCC3)C2=O)C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)C2=O)C2=O)ccc1-[n]1nnnc1 Chemical compound Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2N(CCN(C2)C3CCOCC3)C2=O)C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)C2=O)C2=O)ccc1-[n]1nnnc1 OZAVUGADTXNPNM-UMSFTDKQSA-N 0.000 description 1
- JABPWCQEYKBLQB-YTTGMZPUSA-N Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2N(CCN(CCOC)C2)C2=O)C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)C2=O)C2=O)ccc1-[n]1nnnc1 Chemical compound Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2N(CCN(CCOC)C2)C2=O)C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)C2=O)C2=O)ccc1-[n]1nnnc1 JABPWCQEYKBLQB-YTTGMZPUSA-N 0.000 description 1
- JKBLKDXJVJRKFC-IBGZPJMESA-N Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2NC(NS(C)(=O)=O)=O)C(N)=O)C2=O)C2=O)ccc1-[n]1nnnc1 Chemical compound Cc(cc1N(CCN([C@@H](Cc(cc2)ccc2NC(NS(C)(=O)=O)=O)C(N)=O)C2=O)C2=O)ccc1-[n]1nnnc1 JKBLKDXJVJRKFC-IBGZPJMESA-N 0.000 description 1
- YPPXNUBLLBFRHM-HKBQPEDESA-N N#CC(CC1)CCN1C(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O Chemical compound N#CC(CC1)CCN1C(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O YPPXNUBLLBFRHM-HKBQPEDESA-N 0.000 description 1
- YZQQAHOSVBBSCZ-QHCPKHFHSA-N NC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O Chemical compound NC([C@H](Cc(cc1)ccc1NC(Oc1ccccc1)=O)N(CCN(c1cc(Cl)ccc1-[n]1nnnc1)C1=O)C1=O)=O YZQQAHOSVBBSCZ-QHCPKHFHSA-N 0.000 description 1
- IMLXLGZJLAOKJN-OLQVQODUSA-N N[C@H](CC1)CC[C@H]1O Chemical compound N[C@H](CC1)CC[C@H]1O IMLXLGZJLAOKJN-OLQVQODUSA-N 0.000 description 1
- FDUNRKJXFZFUCS-UHFFFAOYSA-N Nc(c(N(CCN(C1=O)[N+]([O-])=O)C1=O)c1)ccc1Cl Chemical compound Nc(c(N(CCN(C1=O)[N+]([O-])=O)C1=O)c1)ccc1Cl FDUNRKJXFZFUCS-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N O=C1NCCNC1 Chemical compound O=C1NCCNC1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- JQNSUWHWLBLHQL-UHFFFAOYSA-N OC(C1)COC11CCNCC1 Chemical compound OC(C1)COC11CCNCC1 JQNSUWHWLBLHQL-UHFFFAOYSA-N 0.000 description 1
- BXBJZYXQHHPVGO-UHFFFAOYSA-N OC(CC1)CCC1=O Chemical compound OC(CC1)CCC1=O BXBJZYXQHHPVGO-UHFFFAOYSA-N 0.000 description 1
- SJZJWAKZYDZIRR-RXTXSJHVSA-N OC(CC1)CCC1N(CCN1c2ccc(C[C@@H](C(Nc(cc3)cc4c3[nH]c(C(O)=O)c4)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)cc2)CC1=O Chemical compound OC(CC1)CCC1N(CCN1c2ccc(C[C@@H](C(Nc(cc3)cc4c3[nH]c(C(O)=O)c4)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)cc2)CC1=O SJZJWAKZYDZIRR-RXTXSJHVSA-N 0.000 description 1
- ODTIJIZOATWHFD-OVUYURIWSA-N OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C4COCCC4)C3=O)N(CCN(c(cc(cc3)Cl)c3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O Chemical compound OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(C3)C4COCCC4)C3=O)N(CCN(c(cc(cc3)Cl)c3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O ODTIJIZOATWHFD-OVUYURIWSA-N 0.000 description 1
- AFGJCHQXXPQHFO-RULBIBMZSA-N OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(CC3COCC3)C3)C3=O)N(CCN(c(cc(cc3)Cl)c3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O Chemical compound OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3N(CCN(CC3COCC3)C3)C3=O)N(CCN(c(cc(cc3)Cl)c3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O AFGJCHQXXPQHFO-RULBIBMZSA-N 0.000 description 1
- UKXSXYBJPFBUSO-PMERELPUSA-N OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3NC(N3CCCCC3)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O Chemical compound OC(c1cc2cc(NC([C@H](Cc(cc3)ccc3NC(N3CCCCC3)=O)N(CCN(c3cc(Cl)ccc3-[n]3nnnc3)C3=O)C3=O)=O)ccc2[nH]1)=O UKXSXYBJPFBUSO-PMERELPUSA-N 0.000 description 1
- HRRACPBISMUTFQ-RNAHPLFWSA-N OC[C@@H](CCC1)N1C(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O Chemical compound OC[C@@H](CCC1)N1C(Nc1ccc(C[C@@H](C(Nc2ccc3[nH]c(C(O)=O)cc3c2)=O)N(CCN(c2cc(Cl)ccc2-[n]2nnnc2)C2=O)C2=O)cc1)=O HRRACPBISMUTFQ-RNAHPLFWSA-N 0.000 description 1
- VLAZLCVSFAYIIL-RXMQYKEDSA-N OC[C@@H]1OCCNC1 Chemical compound OC[C@@H]1OCCNC1 VLAZLCVSFAYIIL-RXMQYKEDSA-N 0.000 description 1
- VLAZLCVSFAYIIL-YFKPBYRVSA-N OC[C@H]1OCCNC1 Chemical compound OC[C@H]1OCCNC1 VLAZLCVSFAYIIL-YFKPBYRVSA-N 0.000 description 1
- UJAHHSQVNVQNNX-UHFFFAOYSA-N [O-][N+](c(cc12)ccc1[nH]c(C(O)=O)c2Cl)=O Chemical compound [O-][N+](c(cc12)ccc1[nH]c(C(O)=O)c2Cl)=O UJAHHSQVNVQNNX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911147949 | 2019-11-21 | ||
| CN201911147949.3 | 2019-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202120499A TW202120499A (zh) | 2021-06-01 |
| TWI749881B true TWI749881B (zh) | 2021-12-11 |
Family
ID=75979946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109140529A TWI749881B (zh) | 2019-11-21 | 2020-11-19 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN114728914B (fr) |
| TW (1) | TWI749881B (fr) |
| WO (1) | WO2021098817A1 (fr) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026996A (zh) * | 2008-03-13 | 2011-04-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| WO2018041122A1 (fr) * | 2016-08-31 | 2018-03-08 | 江苏恒瑞医药股份有限公司 | Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique |
| CN107793396A (zh) * | 2016-08-31 | 2018-03-13 | 江苏恒瑞医药股份有限公司 | 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用 |
| JP2019077704A (ja) * | 2014-01-31 | 2019-05-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124511C1 (ru) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
| US20080221063A1 (en) * | 2005-07-08 | 2008-09-11 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa |
| ES2595240T3 (es) * | 2012-07-09 | 2016-12-28 | Lupin Limited | Derivados de tetrahidroquinazolinona como inhibidores de PARP |
-
2020
- 2020-11-19 TW TW109140529A patent/TWI749881B/zh active
- 2020-11-20 WO PCT/CN2020/130361 patent/WO2021098817A1/fr active Application Filing
- 2020-11-20 CN CN202080079337.XA patent/CN114728914B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026996A (zh) * | 2008-03-13 | 2011-04-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| JP2019077704A (ja) * | 2014-01-31 | 2019-05-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| WO2018041122A1 (fr) * | 2016-08-31 | 2018-03-08 | 江苏恒瑞医药股份有限公司 | Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique |
| CN107793396A (zh) * | 2016-08-31 | 2018-03-13 | 江苏恒瑞医药股份有限公司 | 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202120499A (zh) | 2021-06-01 |
| CN114728914B (zh) | 2023-05-12 |
| CN114728914A (zh) | 2022-07-08 |
| WO2021098817A1 (fr) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11046697B2 (en) | Compounds and compositions useful for treating disorders related to NTRK | |
| JP2021513534A (ja) | 抗癌剤として有用なテトラヒドロキナゾリン誘導体 | |
| EP2588466B1 (fr) | Dérivés de la 5-amino-3,6-dihydro-1H-pyrazin-2-one utiles en tant qu'inhibiteurs de la bêta-sécrétase (BACE) | |
| RU2701156C2 (ru) | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах | |
| EP3860989B1 (fr) | Pyrrolines fusionnées qui agissent en tant qu'inhibiteurs de la protéase 30 (usp30) spécifique de l'ubiquitine | |
| ES2800313T3 (es) | Compuestos de heteroarilo bicíclico sustituidos | |
| JP2018527329A (ja) | Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体 | |
| EP3632903B1 (fr) | Composé tenant lieu de modificateur autophage, son procédé de préparation et son application | |
| JP2022547952A (ja) | Ｂｒｄ９二機能性分解誘導薬及びその使用方法 | |
| EP3707142B1 (fr) | Dérivés de pyrrolopyrazine à utiliser en tant qu'inhibiteurs de l'intégrine alpha v | |
| KR20210107046A (ko) | 거대고리 화합물 및 질환 치료에서 이들의 용도 | |
| RU2747318C2 (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2 | |
| WO2015178955A1 (fr) | Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase | |
| WO2021113625A1 (fr) | Composés et procédés de modulation de cd73 et leurs indications | |
| CN104411696A (zh) | 环己烷-1,2′-萘-1′,2″-咪唑化合物及其作为bace抑制剂的用途 | |
| KR20220106778A (ko) | 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체 | |
| CA3225439A1 (fr) | Inhibiteurs de cdk2 et leurs procedes d'utilisation | |
| CN104394862A (zh) | 色满化合物 | |
| TW201808908A (zh) | 因子XIa抑制劑 | |
| US20180334436A1 (en) | Tetrahydroisoquinoline derivatives | |
| TWI749881B (zh) | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 | |
| WO2021110076A1 (fr) | Dérivés d'oxamide, leur procédé de préparation et leur utilisation en médecine | |
| WO2022083706A1 (fr) | Sels de composés inhibiteurs de fxia, leur procédé de préparation et leur utilisation pharmaceutique | |
| TW200526642A (en) | Heterocyclic derivatives | |
| NL2031175B1 (en) | Dhcr24 inhibitory compounds |